Biotechnology financing dilemmas and the role of special purpose entities

Nature Biotechnology

Volumn 22, Issue 3, 2004, Pages 271-277

  Schiff, Leora ^a,b   Murray, Fiona ^b  

^a MIT Sloan School of Management ^*

^b MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOTECHNOLOGY COMPANIES;

DRUG PRODUCTS; FINANCE;

BIOTECHNOLOGY;

ABCIXIMAB; ALGLUCERASE; ALITRETINOIN; ALTEPLASE; BIOMATERIAL; CAPROMAB PENDETIDE IN 111; CARMUSTINE; CATHFLO ACTIVASE; ETANERCEPT; GAMMA1B INTERFERON; HUMAN GROWTH HORMONE; HYALIN; MYOSIN ANTIBODY IN 111; PHOSPHOLIPID; POLYPROPYLENE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RECOMBINANT THYROTROPIN; SOMATREM; TENECTEPLASE;

BIOTECHNOLOGY; CAPITAL; DIAGNOSTIC KIT; DRUG MANUFACTURE; FINANCIAL MANAGEMENT; HISTORY; INDUSTRY; INVESTMENT; MANAGEMENT; ORGANIZATION; PRIORITY JOURNAL; REVIEW; SPECIAL PURPOSE ENTITY;

BIOTECHNOLOGY; CAPITAL FINANCING; FINANCIAL MANAGEMENT; FINANCIAL SUPPORT; INTERINSTITUTIONAL RELATIONS; INVESTMENTS; UNITED STATES;

EID: 1542276740     PISSN: 10870156     EISSN: None     Source Type: Journal    
DOI: 10.1038/nbt0304-271     Document Type: Review

References (5)

1. Recombinant Capital. Year-end '98 financing numbers: A Tale of Two Biotechs. Signals Magazine, (http://www.signalsmagazine.com) February 7, 1999.
2. Ernst & Young LLP. Convergence: Ernst and Young's Biotechnology Industry Report, Millennium Edition (Ernst & Young, New York, 2000).
3. Solt, M.E. SWORD financing of innovation in the biotechnology industry. Financial Management 22, 173-187 (1993).
4. Edwards, M. et al. Value creation and sharing among universities, biotechnology and pharma. Nat. Biotechnol. 21, 618-624 (2003).
5. Financial Accounting Standards Board. Exposure Draft, Proposed Interpretation: Consolidation of Certain Special Purpose Entities, an interpretation of ARB NO. 51, File ref. no. 1082-200 (FASB, Norwalk, CT, June 28, 2002).